Skip to main content

Table 4 Pathologic results after neoadjuvant chemotherapy and response to chemotherapy

From: Response to neoadjuvant chemotherapy based on pathologic complete response in very young patients with ER-positive breast cancer: a large, multicenter, observational study

Characteristic ER-Positive ER-Negative
Age<35 35≤Age<50 P-value Age<35 35≤Age<50 P-value
(N = 147) (N = 901) (N = 134) (N = 663)
Postoperative T stage
 ypT0, ypTis 6 (4.1) 27 (3.0) 0.638 28 (20.9) 111 (16.8) 0.310
 ypT1-ypT4 141 (95.9) 874 (97.0)   106 (79.1) 552 (83.2)  
 ypT1 47 (32.2) 351 (39.1)   29 (21.6) 188 (28.4)  
 ypT2 69 (47.3) 348 (38.8)   45 (33.6) 204 (30.8)  
 ypT3 22 (15.1) 158 (17.6)   23 (17.2) 94 (14.2)  
 ypT4 2 (1.4) 14 (1.3)   0 (0) 0 (0)  
Postoperative N stage
 ypN0 55 (37.4) 296 (32.9) 0.515 77 (57.5) 301 (45.4) 0.016
 pN1-ypN3 92 (62.6) 604 (67.0)   52 (38.8) 323 (47.9)  
Pathologic response
 Complete: breast and axilla 7 (4.8) 37 (4.1) 0.713 26 (19.4) 74 (11.2) 0.009
 Complete: breast-only 1 (0.7) 3 (0.3) 1.000 3 (2.2) 45 (6.7) 0.006
  1. NOTE: Data are presented as No. (%) unless otherwise specified
  2. ER estrogen receptor